Profile data is unavailable for this security.
About the company
Almirall SA is a Spain-based company principally engaged in the pharmaceuticals manufacture. The Company focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating agents. The Company's activities are divided into four business segments: Own network, which focuses on the commercialization of pharmaceuticals through own brand names; Licenses, which sells product rights to third parties; Research and development (R&D), which is responsible for the creation of drug candidates, as well as Dermatology, which includes sale of dermatological medicines in the United States. The Company operates through numerous subsidiaries in Europe, the Americas, Africa, Asia and Australia.
- Revenue in EUR (TTM)947.57m
- Net income in EUR-44.90m
- Incorporated--
- Employees2.00k
- LocationAlmirall SARonda General Mitre, 151BARCELONA 08022SpainESP
- Phone+34 932913000
- Fax+34 932913681
- Websitehttps://www.almirall.es/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Caplin Point Laboratories Ltd | 206.85m | 55.76m | 1.67bn | 859.00 | 30.02 | 5.81 | 26.38 | 8.07 | 64.73 | 64.73 | 240.10 | 334.54 | 0.6861 | 2.28 | 3.40 | 21,312,920.00 | 18.62 | 19.83 | 21.36 | 22.82 | 58.72 | 53.38 | 27.14 | 25.39 | 5.07 | 932.86 | 0.0009 | 9.06 | 15.50 | 21.17 | 21.48 | 20.95 | 17.47 | 17.84 |
| 3SBio Inc | 1.11bn | 218.55m | 1.67bn | 5.61k | 7.78 | 0.8822 | 6.17 | 1.51 | 0.7314 | 0.7314 | 3.71 | 6.45 | 0.3575 | 1.52 | 6.87 | 1,671,849.00 | 7.25 | 7.44 | 10.26 | 9.29 | 85.94 | 82.91 | 20.27 | 21.50 | 1.57 | 141.55 | 0.1998 | -- | 13.84 | 11.26 | -19.13 | 3.94 | 8.78 | -- |
| Tarsus Pharmaceuticals Inc | 123.75m | -128.26m | 1.69bn | 244.00 | -- | 7.46 | -- | 13.62 | -3.76 | -3.76 | 3.58 | 6.22 | 0.4022 | 6.37 | 7.51 | 531,233.60 | -41.68 | -31.56 | -48.37 | -33.82 | 92.97 | -- | -103.64 | -242.59 | 5.38 | -- | 0.2319 | -- | -32.42 | -- | -118.86 | -- | 279.39 | -- |
| Jiangxi Tianxin Pharmaceutical Co Ltd | 264.91m | 73.53m | 1.72bn | 2.47k | 23.42 | 2.93 | -- | 6.49 | 1.27 | 1.27 | 4.58 | 10.18 | 0.3977 | 2.75 | 10.26 | 812,720.60 | 11.04 | -- | 11.82 | -- | 41.64 | -- | 27.76 | -- | 6.39 | -- | 0.0234 | -- | -18.34 | -- | -23.51 | -- | -- | -- |
| Haw Par Corporation Ltd | 169.49m | 166.21m | 1.75bn | 595.00 | 10.55 | 0.6696 | 10.29 | 10.35 | 1.06 | 1.06 | 1.08 | 16.70 | 0.0653 | 5.06 | 4.98 | -- | 6.41 | 4.73 | 6.61 | 4.85 | 57.06 | 54.42 | 98.06 | 85.35 | 4.49 | -- | 0.0097 | 45.57 | 27.44 | -0.4885 | 46.02 | 3.88 | 18.24 | 5.92 |
| Jiang Zhong Pharmaceutical Co Ltd | 556.91m | 99.35m | 1.77bn | 4.01k | 17.73 | 3.60 | -- | 3.17 | 1.20 | 1.20 | 6.71 | 5.91 | 0.6828 | 3.58 | 15.12 | 1,052,061.00 | 13.36 | 10.82 | 20.72 | 15.08 | 63.72 | 65.02 | 19.56 | 18.17 | 0.8833 | -- | 0.0004 | 82.88 | 13.00 | 20.12 | 18.40 | 8.54 | 11.47 | 40.99 |
| Almirall SA | 947.57m | -44.90m | 1.77bn | 2.00k | -- | 1.21 | -- | 1.87 | -0.2127 | -0.2127 | 4.56 | 6.87 | 0.4069 | 1.34 | 6.53 | 497,675.40 | -1.93 | 0.922 | -2.17 | 1.08 | 76.69 | 78.06 | -4.74 | 2.48 | 1.99 | 394.32 | 0.1912 | -- | 3.62 | 3.40 | -998.72 | -- | -23.27 | -- |
| BrightGene Bio-Medical Technology Co Ltd | 163.76m | 24.81m | 1.78bn | 1.16k | 71.43 | 5.72 | -- | 10.86 | 0.4466 | 0.4466 | 2.96 | 5.57 | 0.2522 | 1.63 | 3.50 | 1,074,862.00 | 2.91 | 6.53 | 3.57 | 7.93 | 54.97 | 56.93 | 11.55 | 19.90 | 1.18 | 4.53 | 0.4841 | 29.31 | 15.94 | 23.68 | -15.51 | 22.56 | 29.13 | -- |
| Astrazeneca Pharma India Ltd | 167.72m | 9.26m | 1.78bn | 940.00 | 192.45 | 23.20 | 153.62 | 10.62 | 32.76 | 32.76 | 593.93 | 271.74 | 1.27 | 2.52 | 10.63 | 15,792,680.00 | 6.99 | 11.78 | 11.44 | 19.62 | 44.88 | 54.64 | 5.52 | 10.27 | 1.44 | 134.82 | 0.0246 | 25.62 | 29.17 | 12.21 | 62.66 | 24.29 | -10.46 | -- |
| Endo Inc | -95.47bn | -95.47bn | 1.79bn | 3.00k | -- | 1.02 | -- | -- | -- | -- | -- | 23.99 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.52 | -- | 0.5697 | -- | -13.25 | -- | 15.87 | -- | -- | -- |
| Nippon Shinyaku Co., Ltd. | 953.08m | 160.92m | 1.80bn | 2.21k | 10.74 | 1.19 | 9.24 | 1.89 | 386.74 | 386.74 | 2,290.53 | 3,486.81 | 0.5956 | 1.29 | 3.36 | 69,711,700.00 | 10.06 | 10.45 | 11.39 | 12.31 | 67.69 | 61.27 | 16.89 | 16.47 | 4.22 | -- | 0.0107 | 32.62 | 2.83 | 5.26 | 13.32 | 9.66 | 45.93 | 12.12 |
| Harmony Biosciences Holdings Inc | 650.99m | 117.07m | 1.81bn | 246.00 | 15.73 | 3.18 | 12.90 | 2.78 | 2.11 | 2.11 | 11.75 | 10.46 | 0.7994 | 24.26 | 9.17 | 2,771,866.00 | 14.38 | 7.46 | 17.12 | 9.08 | 78.65 | 80.58 | 17.98 | 10.46 | 3.20 | -- | 0.2345 | 0.00 | 32.93 | -- | -28.99 | -- | -25.31 | -- |
| Zhejiang Jiuzhou Pharmaceutical Co Ltd | 647.95m | 91.99m | 1.86bn | 4.88k | 20.22 | 1.65 | -- | 2.87 | 0.7749 | 0.7749 | 5.45 | 9.51 | 0.4405 | 1.75 | 4.20 | 1,007,191.00 | 6.28 | 10.10 | 7.67 | 13.69 | 32.61 | 34.64 | 14.25 | 16.26 | 2.48 | -- | 0.0909 | 40.79 | 1.44 | 24.29 | 12.20 | 45.74 | 32.14 | 20.11 |
Data as of Nov 22 2024. Currency figures normalised to Almirall SA's reporting currency: Euro EUR
10.71%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Oddo BHF Asset Management SASas of 31 Oct 2024 | 4.28m | 2.01% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 3.08m | 1.44% |
| Santander Asset Management SA SGIICas of 30 Jun 2024 | 2.62m | 1.23% |
| Caixabank Asset Management SGIIC SAas of 30 Jun 2024 | 2.53m | 1.19% |
| Wellington Management Co. LLPas of 14 Nov 2024 | 2.48m | 1.16% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 2.14m | 1.00% |
| Cobas Asset Management SGIIC SAas of 30 Sep 2024 | 2.01m | 0.94% |
| KBC Asset Management NVas of 30 Jun 2024 | 1.33m | 0.62% |
| Amundi Asset Management SA (Investment Management)as of 06 Nov 2024 | 1.26m | 0.59% |
| Dimensional Fund Advisors LPas of 07 Nov 2024 | 1.14m | 0.54% |
More ▼
Data from 30 Jun 2024 - 13 Nov 2024Source: FactSet Research Systems Inc.
